Titan Pharma Inc (TTNP) 0.7310 $TTNP Titan Prepares For

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Titan Pharma Inc (TTNP) 0.7310 $TTNP

Titan Prepares For Big Summer 2015
Jason Napodano, CFA - at Seeking Alpha - Sat May 16, 7:25AM CDT


Titan Pharmaceutical's (TTNP) Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 4:01PM CDT


Titan Pharmaceuticals Reports First Quarter 2015 Financial Results
Marketwired - Wed May 13, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, today reported financial results for the first quarter ended March 31, 2015.

Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2015 Financial Results
Marketwired - Fri May 08, 1:04PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 1 p.m. EDT / 10 a.m. PDT on Thursday, May 14, 2015 to discuss the company's financial results as of March 31, 2015. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance; and Marc Rubin, M.D., executive chairman. Highlights of the first quarter and financial results will be included in a press release to be issued prior to the call.

Buy Titan Ahead Of Summer Catalyst
Alexander Maxwell - at Seeking Alpha - Fri May 08, 10:13AM CDT


TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach of Fiduciary Duty
Business Wire - Wed Apr 08, 7:21AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Titan Pharmaceuticals, Inc. (OTC:TTNP) ("Titan Pharmaceuticals" or the "Company".

Titan Pharmaceuticals' (TTNP) Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 2:58PM CDT


Stock to Watch: Titan Pharmaceuticals Up 5.2% (TTNP)
Comtex SmarTrend(R) - Tue Mar 31, 10:17AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 5.2% to $0.71 on 1.1x average daily volume. Thus far today, Titan Pharmaceuticals has traded 488,000 shares, vs. average volume of 432,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.3%) and outperformed the S&P 500 (5.2% to the S&P's -0.2%) during today's trading.

Titan Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Tue Mar 31, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the fourth quarter and year ended December 31, 2014.

Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Wed Mar 25, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Wednesday, April 1, 2014 to discuss the company's financial results as of December 31, 2014. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the fourth quarter and full year financial results will be included in a press release to be issued prior to the call.

Penny Stocks Report for Titan Pharmaceuticals, American Green, Banro, Globalstar, IFAN Financial, and Regen BioPharma
PR Newswire - Tue Mar 03, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Titan Pharmaceuticals (OTCBB:TTNP), American Green (OTCMKTS:ERBB), Banro (NYSEMKT:BAA), Globalstar (NYSEMKT:GSAT), IFAN Financial (OTCBB:IFAN), and Regen BioPharma (OTCBB:RGBP).
BAA: 0.38 (+0.07), GSAT: 2.42 (-0.14)

Titan Pharmaceuticals to Present at 27th Annual ROTH Conference
Marketwired - Tue Mar 03, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that Titan President Sunil Bhonsle will present at the 27th annual ROTH Conference on Monday, March 9 at 9:30 a.m. PT at The Ritz-Carlton in Laguna Niguel, Calif.

Traders Get Bullish on Shares of Titan Pharmaceuticals, Shares Up 6.3% (TTNP)
Comtex SmarTrend(R) - Mon Mar 02, 10:08AM CST
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 6.3% to $0.68 on 1.4x average daily volume. Thus far today, Titan Pharmaceuticals has traded 732,000 shares, vs. average volume of 509,000 shares per day. The stock has outperformed the Dow (6.3% to the Dow's 0.7%) and outperformed the S&P 500 (6.3% to the S&P's 0.4%) during today's trading.

New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST

ADMS: 17.91 (+0.07), ACOR: 30.71 (+0.67), NDRM: 13.10 (-0.01), XNPT: 6.17 (+0.23), IPXL: 45.20 (+0.76), ABBV: 65.61 (-0.38), TEVA: 60.19 (-0.04), SNY: 50.40 (-0.12), PRTA: 32.00 (+1.01)

Roth Capital's 4 Reasons To Be Bullish On Titan Pharmaceuticals
TipRanks - at Seeking Alpha - Mon Jan 26, 1:28PM CST
By Sarah Roden Titan Pharmaceuticals ( OTCQB:TTNP ) is a biomedical pharmaceutical company most known for its flagship drug, Probuphine, used to treat opioid addiction. Probuphine has proved to be effective in two clinical studies and one safety...

Titan Pharmaceuticals to Present at 8th Annual OneMedForum
Marketwired - Tue Jan 06, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that its President, Sunil Bhonsle, will present at the 8th annual OneMedForum taking place on January 12-13, 2015 in San Francisco. The presentation is scheduled for Jan. 12 at 11 a.m. in the Public Company Track Room, Marriott Marquis, San Francisco, California.

First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST

IPXL: 45.20 (+0.76), ADMS: 17.91 (+0.07), TEVA: 60.19 (-0.04), ACOR: 30.71 (+0.67), PRTA: 32.00 (+1.01), NDRM: 13.10 (-0.01)

Titan Pharmaceuticals to Present at LD Micro Conference
Marketwired - Mon Dec 01, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that its President, Sunil Bhonsle, will present at the 7th annual LD Micro "Main Event" Micro-Cap Growth Conference on Thursday, Dec. 4 at 8:30 a.m. PT. The conference will be held at the Luxe Sunset Bel Air Hotel, in Los Angeles, Calif.

Enrollment complete in Probuphine Phase 3
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 9:03AM CST


Titan Pharmaceuticals Announces Completion of Enrollment in Phase 3 Study of Probuphine for Opioid Dependence
Marketwired - Thu Nov 20, 5:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced completion of enrollment in the ongoing Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. Study completion is expected to be on schedule by the middle of 2015, paving the way for resubmission of the New Drug Application (NDA) for Probuphine with the U.S. Food and Drug Administration (FDA) later in the year.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 0

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 0

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Lawsuit Filed Alleging Eye Injury from Ozempic Use

Updated Category News Views 165

Parker Waichman LLP Takes Action Against Drug Manufacturer Parker Waichman, a prominent national law firm, is actively filing lawsuits for individuals who assert that they developed NAION after using Novo Nordisk's medications, Ozempic or Wegovy. The firm recently initiated a case for a Florida resident who experienced this severe eye condition after using Ozempic....

Continue Reading
C.H. Robinson Prepares for Upcoming Earnings Conference Call

Updated Category News Views 151

C.H. Robinson's Upcoming Earnings Release and Conference Call C.H. Robinson Worldwide, Inc. (Nasdaq: CHRW), a leading logistics provider, has announced significant plans for its upcoming earnings release. The company is scheduled to share its third quarter 2024 results post market close. On this important day, the company will hold a conference call to delve into the...

Continue Reading
PayPal Surges 14% After Exciting Partnership with OpenAI

Updated Category News Views 173

PayPal's Innovative Partnership with OpenAI Shares of PayPal Holdings Inc (NASDAQ: PYPL) experienced a notable increase of 14.38% in pre-market trading. This rise was sparked by the recent announcement of a deal between the payments giant and OpenAI. This partnership focuses on integrating PayPal's digital wallet into the popular AI platform, ChatGPT. Enabling...

Continue Reading
Unlocking the Future of Ridesharing: Uber and Nvidia's Game Changer

Updated Category News Views 199

Introduction to the Partnership In an exciting development, Uber Technologies Inc (NYSE: UBER) has announced a strategic partnership with Nvidia Corp (NASDAQ: NVDA) aimed at leveraging artificial intelligence (AI) to enhance ridesharing and autonomous vehicle technology. Analyst Justin Post from BofA Securities has enthusiastically maintained a Buy rating on Uber’s...

Continue Reading
Exploring the Future of Organic Infant Formula Market Growth

Updated Category News Views 275

Overview of Organic Infant Formula Market Growth The Organic Infant Formula market has seen remarkable expansion, indicating a shift in parental preferences towards health-conscious choices for their young ones. The market, which had a valuation of USD 20.8 billion in the recent past, is expected to reach an impressive USD 36.04 billion by 2032. This growth trajectory...

Continue Reading